Lifecore Biomedical (LFCR) Expected to Announce Quarterly Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) is anticipated to post its Q2 2026 results after the market closes on Thursday, January 1st. Analysts expect Lifecore Biomedical to post earnings of ($0.11) per share and revenue of $35.3080 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, January 9, 2026 at 12:00 AM ET.

Lifecore Biomedical (NASDAQ:LFCR) last released its earnings results on Monday, April 1st. The company reported ($0.22) EPS for the quarter. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 25.59%.The firm had revenue of $26.54 million for the quarter. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Price Performance

Shares of NASDAQ LFCR opened at $8.09 on Wednesday. Lifecore Biomedical has a twelve month low of $4.76 and a twelve month high of $8.85. The company has a current ratio of 2.80, a quick ratio of 1.67 and a debt-to-equity ratio of 113.76. The company has a market capitalization of $303.13 million, a price-to-earnings ratio of -7.56 and a beta of 0.60. The business has a 50 day simple moving average of $7.61 and a 200-day simple moving average of $7.49.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Lifecore Biomedical in a report on Wednesday, October 8th. KeyCorp began coverage on shares of Lifecore Biomedical in a research report on Wednesday, September 3rd. They issued a “sector weight” rating on the stock. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Lifecore Biomedical currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LFCR. PharVision Advisers LLC bought a new position in Lifecore Biomedical in the 3rd quarter worth about $151,000. Quarry LP acquired a new position in shares of Lifecore Biomedical during the third quarter worth approximately $28,000. Millennium Management LLC boosted its position in shares of Lifecore Biomedical by 99.6% during the third quarter. Millennium Management LLC now owns 135,205 shares of the company’s stock worth $995,000 after buying an additional 67,456 shares during the period. Citadel Advisors LLC grew its holdings in Lifecore Biomedical by 127.1% in the 3rd quarter. Citadel Advisors LLC now owns 66,752 shares of the company’s stock worth $491,000 after buying an additional 37,363 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in Lifecore Biomedical in the 3rd quarter valued at approximately $221,000. 83.36% of the stock is owned by institutional investors and hedge funds.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.